SCHEMBL14745859

SCHEMBL14745859

COC(=O)c1c(OCc2ccccc2)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1cc3cc(C=O)n(C)c3cc1C=CC2

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EDNRB P24530 4/20 0.37
TP53 P04637 2/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 5/20 0.34
MAPT P10636 3/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SRD5A1 P18405 1/20 0.34
SRD5A2 P31213 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GHSR Q92847 1/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745698 0.90 EDNRB (0.37) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL14746154 0.86 EDNRB (0.34) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL14746131 0.84 TSHR (0.35) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL14745797 0.84 EDNRB (0.39) EDNRBTSHRALDH1A1MEN1KMT2A
SCHEMBL18628127 0.81 EDNRB (0.38) EDNRBTSHRALDH1A1MAPTLMNA
SCHEMBL18628123 0.79 EDNRB (0.38) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL14745442 0.77 EGLN1 (0.35) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL17494953 0.74 EDNRB (0.38) EDNRBTP53TSHRALDH1A1MAPT
SCHEMBL14746104 0.73 EGLN1 (0.33) EDNRBTSHRALDH1A1MAPTLMNA
SCHEMBL14745699 0.73 EDNRB (0.40) EDNRBTSHRMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EDNRB 3885/4885TP53 2640/4885TSHR 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.